MU rises +2 to 26/33 (series high, #1) on a +0.82% week to $884.74 (RSI 42.0; -5.3% on Oct 30): quarter and 52-week momentum tests flipped to pass. The quality sweep (Financial 4/4, Mgmt 3/3, Growth 3/3, Earnings 2/2) is intact. Flag: the $1,145 PT predates the Sep 30 FY2026 print and is STALE - the Section-6 math (9.4x FY28 EPS $181.98) points to ~$1,711, queued for judgment re-derivation. Hold $849.25, then the SMA-200 ($746.83); reclaim $978.71. Our 12-month $1,145 (+29%). Next earnings est. ~Dec 16 (Q1 FY27).

TSM slips -1 to 24/33 (#2) on a -2.96% week to $406.13 (RSI 38.3), including -5.95% on Oct 30 that tested the 200-day: quarter momentum (C51) flipped to fail. FX flag CLOSED: the EPS grid was restated to a consistent 32 NTD/USD (TTM EPS $16.69 to $15.37, P/E 24.3x to 26.4x); C33 still passes (it flips above ~$421), so the score is 24/33 either way. The stat-page TTM EPS ($14.94) is ~3% below the restated $15.37 - verify against the TSMC release. Hold $400.16, then $372.72; reclaim $434.92. Our 12-month $510 (+26%). Next earnings est. ~Jan 15, 2027.

GS joins at 24/33 (73%; 21/33 excluding three bank-structure artifacts - current ratio, quick ratio and a negative-cash-flow P/CF pass) on a -3.58% day to $894.55 (RSI 44.9; week +2.15%, quarter -12.9%, 22.5% below the Jul 15 high). Quality is elite for a bank (Mgmt 3/3, Growth 3/3, Earnings 2/2; Q3 EPS $17.01, +39% YoY, ROTE 20.5%) and P/E is low at 12.9x trailing / 12.1x forward with P/B 2.40x, but earnings are peak-cycle (Street FY27 EPS +3.6%), the 5-yr-average P/E test passes by only ~1%, and D/E 671% / interest coverage n/a are structural fails. Ranked below TSM on the tie-break because three of its passes are structural artifacts. Hold $879.50, then $864.12; reclaim $927.73. Our 12-month $1,000 (+12%) vs ~-17% to a 10x trough multiple: a thin margin of safety. Next earnings ~mid-Jan 2027 (unconfirmed).

NVDA slips -1 to 23/33 on a -3.00% week to $204.64 (RSI 35.1; -4.2% on Oct 30, sitting on its 200-day): the quarter-performance test (C52) flipped to fail. The Financial 4/4 + Mgmt 3/3 + Growth 3/3 + Earnings 2/2 quality sweep is intact. Trailing P/E 25.9x passes C33 against 27.4x with a modest cushion. Hold $204.39, then $200.92; reclaim $221.75. Our 12-month $315 (+54%). Next earnings Nov 17 (AMC, confirmed).

UBER holds 22/33 (flat) on a -2.17% week to $65.25 (RSI 35.8), after a new 52-week low of $64.04 on Oct 29; no flips and all three momentum tests fail. Still among the cheapest valuation profiles in the series, but Financial condition (3/4) is not a clean sweep. Flag: the workbook TTM EPS ($4.24) differs from the stat block ($4.58) on a different quarter basis; all four quarters will be re-based at the Nov 4 roll. ACCUMULATE ON WEAKNESS stands. Hold $64.67, then $64.04; reclaim $71.21. Our 12-month $100 (+53%). Next earnings Nov 4 (BMO, confirmed).

GOOGL slips -1 to 21/33 on a -12.61% week to $279.84 (RSI 21.4, deeply oversold) after the Q3 print (Oct 28 AMC; -12.64% gap on Oct 29, its worst earnings reaction on record): revenue $127.6B (+24.6%), Cloud $30.7B (+103%) with a 36.2% operating margin, backlog ~$561B, but capex $51.4B, FCF -$9.1B and GAAP EPS $2.12 vs ~$3.00 consensus (an $8.7B equity-securities loss, ~$0.55/share; operational EPS ~$2.67). Figures are from secondary sources, not the 8-K. C12 and C38 flipped to pass; C28, C29 and C53 flipped to fail. TTM EPS $19.15 still carries Q2 gains, so the 14.6x P/E is an artifact. The $430 PT (Section-6 math: 31.1x on $13.82 = $429.8) needs a judgment re-derivation; it sits above the analyst average ($406.55). Hold $276.92, then $270.70; reclaim $283.82. Our 12-month $430 (+54%). Next earnings est. ~Feb 2027.

VST holds 21/33 (flat) on a -1.28% week to $138.37 (RSI 42.0); no flips. D/E ~355% (Financial 1/4) remains the structural caveat and momentum is weak. Flag: Section 6 (E77 $8.38) does not reconcile to the $190 PT, which is built on FY27 ~$10.98. Hold $135.86, then $132.66; reclaim $140.95, then $145.07. Our 12-month $190 (+37%). Next earnings Nov 6 (BMO, confirmed).

AMZN slips -2 to 20/33 on a -3.08% week to $240.35 (RSI 38.3) after the Q3 print (Oct 29 AMC): revenue $201.9B (+12.1%), AWS $46.0B (+39%), operating income $28.1B, but capex $77.3B vs operating cash flow $42.4B left Q3 FCF at -$34.8B (TTM -$46.9B); GAAP EPS $1.89 vs $1.95 a year ago, a slight miss, and the first clean quarter with no Anthropic gain. C14 flipped to pass; C28, C29 and C52 flipped to fail. TTM EPS $12.37 still carries H1 gains. Section 6 (31.8x on $9.90 = $314.8) supports the PT. Q4 guidance not captured. Hold $229.36, then $226.65; reclaim $243.40, then $254.28. Our 12-month $315 (+31%). Next earnings est. ~Feb 2027.

AMAT rises +1 to 20/33 on a +3.41% week to $390.09 (RSI 36.3), after a -26% month; a -7.5% reversal on Oct 30 is unverified. C51 flipped to pass. Quality stays flawless (Mgmt 3/3, Growth 3/3, Earnings 2/2) and the stock sits below both the SMA-200 ($444.51) and SMA-50 ($457.66). Hold $372.80, then $360; reclaim $426.52. Our 12-month $495 (+27%). Next earnings Nov 12 (AMC).

BABA holds 19/33 (flat) on a -1.61% week to $98.04 (RSI 29.5, oversold); no flips. Deep-value contrarian profile: cheap on P/E, but ROIC trails WACC and price is far below the SMA-50 ($109.67) and SMA-200 ($126.24). Flags: ADS EPS carries FX translation noise, the $10.2B secondary placement is not in the share count, and Section-6 E77 ($7.94) differs from the ~$8.26 note. Hold $97.48, then $95.19; reclaim $100.96. Our 12-month $150 (+53%). Next earnings est. ~Nov 24.

DELL slips -2 to 19/33 on a -7.04% week to $424.30 (RSI 35.7), including -10.8% on Oct 30 (cause not verified): C51 and C52 flipped to fail. Negative book equity keeps P/B, ROE and D/E n.m. Flag: the Section-6 step-2 multiple (~21.3x, ~$450) is older than the $575 PT. Hold $413.00, then $405.37; reclaim $441.08, then $475.51; the SMA-50 ($513.89) is far above. Our 12-month $575 (+36%). Next earnings Nov 24 (AMC, confirmed).

AXP joins at 19/33 (HOLD) on a +1.88% week to $319.11 (RSI 53.8): a premium card issuer + network - Management 3/3, Growth 3/3, Earnings 2/2 - with Financial 1/4 STRUCTURAL (current/quick ratio n.m., D/E 168%, interest coverage n/a; the quick-ratio pass is a convention artifact), Valuation 7/15 at 18.0x trailing / 15.8x FY27 and momentum 1/3 (price 2.2% below the SMA-200). Flags: Q3 GAAP EPS $5.42 (+31%) includes a one-time $1.11 GBTG gain (adjusted $4.68, +13%, would fail C29); OCC consent order and a 5% workforce restructuring; C34 (P/E 17.96 vs 5-yr avg 17.53) is razor-thin. Hold $317, then $311.40; reclaim $326.07. Our 12-month $350 (+10%) vs a lender-like 13x bear case of ~$262 (-18%). Next earnings est. late Jan 2027 (unconfirmed).

FCX joins at 19/33 (HOLD) at $62.47, after a -5.55% Friday (week -4.16%; RSI 30.2, oversold edge) that left it below the SMA-200 ($65.21) and SMA-50 ($71.58). Q3 (Oct 27) beat on price - adj EPS $0.88 vs $0.82-0.83, GAAP +76% YoY - but 2026/2027 copper-sales guidance was trimmed again and 2027 capex rose to $5.2B. Mgmt 3/3, Earnings 2/2 and Financial 3/4 (quick ratio fails); Valuation 6/15, Growth 2/3 (dividend flat since 2022), Momentum 1/3. Flags: cheap only on forward peak-price EPS (14.4x FY27 vs 26.2x trailing; each 10c/lb copper is ~$0.15 of EPS, est.); trailing PEG uses a normalized 14% denominator and C46/C47 are rebound artifacts; C34 passes by <1 pt on an estimated P/E grid; FY27 consensus ($4.33) is pre-Q3. Hold $61.43, then $58.19; reclaim $65.21. Our 12-month $74 (+18.5%). Next earnings est. ~Jan 21, 2027.

NFLX holds 18/33 (flat) on a -5.73% week to $62.08 (RSI 30.6, oversold), setting a new 52-week low of $61.39; no flips and momentum is 0/3, with price well below the SMA-50 ($72.67) and SMA-200 ($81.60). The Q3 print (Oct 20: EPS $0.87, +47%) was followed by a soft Q4 guide and a Wolfe downgrade. Our PT stays $115 (30.3x FY27 EPS of $3.80, an estimate). ACCUMULATE ON WEAKNESS. Hold $61.39, then ~$60 (round-number estimate); reclaim $63.05, then $65.85. Our 12-month $115 (+85%). Next earnings est. ~Jan 20, 2027.

LLY joins at 18/33 (55%, HOLD) on a +11.31% week to $1,417.54 (RSI 77.9, overbought; +31.9% YTD, +23.3% on the month; all-time high $1,449.68), after the Oct 29 Q3 beat-and-raise: revenue $24.4B (+39%), FY2026 guide lifted to $91-92B and non-GAAP EPS $35.00-36.00 after $4.57/sh of acquired IPR&D. Quality is elite (Mgmt 3/3, Growth 3/3, Momentum 3/3; ROIC 42.7%), but Valuation is 5/15 (46x trailing GAAP, 30x FY2027, 31x book), Financial 1/4 (quick 0.64, D/E 123%) and Earnings 1/2 (GAAP EPS +16.3% misses the +19% bar only on IPR&D). Flags: PEG 1.40 uses the 32.8% consensus-growth denominator (flip-prone near $1,500); FY2027 EPS $47.22 is pre-print consensus; two drugs = 66% of revenue. Hold $1,373.70, then $1,330; reclaim $1,449.68. Our 12-month $1,510 (+6.5%) vs a market-multiple downside anchor of ~$1,294 (-8.7%). Next earnings ~Feb 4, 2027 (BMO, unconfirmed).

SOFI holds 17/33 (flat) on a +14.68% week to $16.76 (RSI 57.0), after the Q3 print (Oct 27 BMO): adjusted net revenue $1,371M (+44%), diluted EPS $0.18 vs $0.11 (+64%, consensus ~$0.17), members 17.07M, FY26 EPS guide raised to ~$0.61 and a first FY27 guide of ~$0.90 EPS / $6.4B revenue; the stock gained +13.4% on the day and then gave back -4.83% on Oct 30. C43 is a razor-thin fail (PEG x 1.25 = 1.0024 vs the 1.0 limit). Flags: the $19 PT (21.1x multiple) may need re-derivation, since the FY27 guide implies ~$21 at the old 23.8x; the stat page (beta, analyst target, short interest) is carried from Oct 23. Hold $16.58, then $15.44; reclaim $17.63, then $17.79. Our 12-month $19 (+13%). Next earnings est. ~late Jan 2027.

VRT holds 17/33 (flat) on a +19.65% week to $232.50 (RSI 51.5; +16.5% on the Oct 28 print, then -5.46% on Oct 30). Q3 (Oct 28 BMO): net sales $4,313M (+61%) vs ~$3.75B consensus, GAAP EPS $1.95 vs $1.02, adjusted EPS $2.21 vs ~$1.82 (+78%), organic orders >100%, FY26 adjusted EPS guide $7.10-7.20. C47 flipped to fail and C51 to pass. Flags: the $355 PT (39.5x FY27 $8.98, Section 6 = $354.71) rests on pre-print FY27 consensus; quick ratio (0.95) and D/E (70%) were not re-cut. Hold $225.09, then $208.56; reclaim $242.61. Our 12-month $355 (+53%). Next earnings ~Feb 2027 (unconfirmed).

MRVL slips -1 to 17/33 on a -14.05% week to $196.40 (RSI 34.0): -13.24% on Oct 29 and -10.05% on Oct 30, with the cause unverified - C51 flipped to fail. Our $235 PT sits only ~20% above price after the drop. Hold $190.15, then the SMA-200 ($183.20); reclaim $207.61, then $218.34. Our 12-month $235 (+20%). Next earnings est. ~Dec 1.

AMD joins at 16/33 (48%, HOLD) after a -10.88% Friday to $504.80 (RSI 39.7; -17.5% on the month, 23% below the $658.52 high) on Intel's weak Q4 guide. Quality is strong - Financial 4/4, Mgmt 3/3, Earnings 2/2 (Q2 revenue +50%, Data Center +107%, GAAP EPS $1.39 vs $0.53) - but Valuation is only 2/15 at 129x trailing GAAP / ~32x FY27 consensus ($15.76), and ROIC 9.8% sits below the ~17.7% WACC. Flags: no dividend (C25 fails); trailing PEG uses a normalized 76% denominator; the two forward-PEG passes are growth artifacts; C34 misses its 126x five-year average by only ~2.5% (flips below ~$492). Price is above the 200-day ($410) but below the 20-day ($570) and 50-day ($548). Hold $492.21, then $477.57; reclaim $531.28. Our 12-month $535 (+6%; no-premium anchor ~$432, -14.5%). Next earnings Tue Nov 3 (AMC, confirmed).

TMO joins at 16/33 (48%) HOLD on a +3.44% week to $697.00 (RSI 59.2, +25% on the year, 21% above the SMA-200 of $551.37): Mgmt 3/3 + Growth 3/3 + Momentum 3/3, but Valuation only 2/15 (36.7x GAAP / ~28x adjusted trailing, 25.3x FY2027) and Financial 2/4 (D/E 75%, interest cover 5.9x). Q3 (Oct 21) beat on adjusted EPS ($6.68 vs $6.40) and guidance was raised; GAAP EPS grew only 8.7%. Flag: Growth 3/3 passes on ADJUSTED 5-yr EPS growth only (GAAP negative). Hold $679, then $662.50; reclaim $711.86. Our 12-month $714 (+2.4%) is fair value, below the Street's $751. Next earnings ~late Jan 2027 (Q4 2026, est.).

PLTR slips -2 to 15/33 on a -6.42% week to $184.11 (RSI 41.9), just under its SMA-50 ($186.90): C51 and C53 flipped to fail. The GARP paradox persists (trailing P/E fails outright while forward PEG passes) and price is ~3% BELOW our $190 PT, leaving almost no margin of safety. Hold $180.81, then $175; reclaim $186.90, then $196.42. Our 12-month $190 (+3%). Next earnings Nov 2 (AMC).

HOOD slips -1 to 14/33 on a -10.60% week to $84.99 (RSI 29.3, oversold; -7.21% on Oct 30) after the Q3 print (Oct 27 AMC): revenue $1,424M (+12%, a record), diluted EPS $0.51 vs $0.61 (-16%, including a $0.07 loss on the Robinhood Ventures fund), adjusted EPS $0.60 vs ~$0.54-0.55 consensus, net deposits $15.7B, 2026 adjusted-opex outlook trimmed to $2.675-2.75B. C29 flipped to fail. Flags: the FY26 estimate ($2.31) looks high vs YTD GAAP $1.51, and the $100 PT (32.4x on a pre-print FY27 $3.09) was not refreshed. Hold $82.00, then $78.93; reclaim $92.59. Our 12-month $100 (+18%). Next earnings ~Feb 2027 (unconfirmed).

AAPL slips -1 to 13/33 on a -0.89% week to $344.63 (RSI 55.4): C51 flipped to fail. Elite quality at a full valuation: buyback-inflated ROE/D/E read through ROIC ~104% and net cash. Price is ~4% above our $330 PT, so there is no margin of safety. Hold $342.08, then $333.04; reclaim and extend above $351.73. Our 12-month $330 (-4%). Next earnings Nov 2 (AMC, confirmed) - the next Tier-3 roll.

GLW holds 13/33 (flat) on a -0.31% week to $123.31 (RSI 35.9; -4.3% on Oct 30; -23% on the month, ~20% below the SMA-200) after the Q3 print (Oct 27 BMO): GAAP sales $4,855M (+18%), GAAP EPS $0.78 vs $0.50; CORE sales $5,081M (+19%), core EPS $0.91 (+36%) vs guide $0.85-0.89; Optical Communications $2,379M (+44%); Q4 guide core sales $5.2-5.3B, core EPS $0.96-1.00 vs ~$0.93 consensus. C29 flipped to pass and C47 to fail. Core revenue exceeds GAAP (never mix them). Flags: FY27 consensus ($4.31) is pre-print; the stat page still shows a $1.12/yr dividend, so the 'frozen' claim needs verification. Hold $120.48, then $114.50; reclaim $133.24. Our 12-month $150 (+22%). Next earnings est. ~late Jan 2027.

IREN holds 12/33 (flat, no flips) on a -3.83% week to $23.95 (new 52-week low $23.06; RSI 30.2), well below the SMA-50 ($37.79) and SMA-200 ($44.36). Momentum 0/3, negative GAAP earnings, high short interest and an Altman Z of 0.98 (distress zone). The $65 PT is asset/contract-based, not multiple-based (+171%). Supports: $23.06, then round levels near $22 and $20 (estimates). Reclaim $24.93. Next earnings Nov 5 (AMC, confirmed).

CRWD joins at 11/33 (33%) HOLD on a -2.8% week to $250.43 (-4.1% Friday; RSI 49.9; +86% over 52 weeks, +35% on the quarter). A first-rate franchise (ARR $5.84B, +25%, record net new ARR, 30% FCF margin, $4.2B net cash) on a GAAP break-even income statement with stock comp ~equal to non-GAAP profit; Valuation 0/15 at ~48x sales and ~155x FY28 non-GAAP EPS (P/E n.m.). All figures are post the 4:1 split (Jul 2, 2026). Price is 33% above the SMA-200 ($167) and 4% above the SMA-50 ($240.25). Hold $240.25, then $227.38; reclaim $261.15, then $275. Our 12-month $210 (-16%, below the price and the Street's $247 average). Q2 FY27 reported Aug 26; next earnings Dec 1 (AMC, est.).

DKNG slips -1 to 10/33 AVOID on a flat 0.00% week at $20.91 (RSI 51.8): a flat week fails the positive-return test, flipping C51 to fail. Financial 0/4 and thin GAAP earnings cap the score; price is still below the SMA-50 ($21.87) and SMA-200 ($24.25). Supports $20.08, $19.94, then $18.35. Flag: Section-6 E77 $1.00 x 33.3 = $33.3 vs the $30 PT (a ~10% haircut). Our 12-month $30 (+43%) prices normalized earnings power that does not exist yet. Next earnings Nov 5 (AMC, confirmed).

SNOW slips -2 to 6/33 AVOID, the series floor, on a -5.95% week to $306.08 (RSI 39.6; -7.3% on Oct 30 on 2x volume, cause not verified): C51 and C52 flipped to fail. Valuation 0/15 on negative GAAP EPS (IF-guards hold). Price is ~12% below our $350 PT and well above the SMA-200 ($239.14). Hold $302.24, then $295.26; reclaim $315. Our 12-month $350 (+14%). No earnings in the window; next est. ~Dec 2 (AMC).